Medical Reversals in Family Practice: A Review

Alyson Haslam, PhD1,*, Catherine Livingston, MD, MPH2, Vinay Prasad, MD, MPH3

1 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
2 School of Medicine, Oregon Health & Science University, Portland, Oregon
3 Division of Hematology Oncology, Knight Cancer Institute, and Center for Health Care Ethics, Oregon Health & Science University, Portland, Oregon

A R T I C L E   I N F O

Article history:
Received 4 September 2019
Accepted 14 February 2020

Key words:
arthroscopic surgery
cardiovascular disease
medical reversal
opioid use
primary care

A B S T R A C T

Background: Primary care physicians are challenged by the need to stay abreast of current research on a wide variety of topics in an environment of time constraints, evolving literature, and misinformation on health topics that are sometimes promulgated to the public.

Objective: We sought to identify and discuss common clinical situations encountered in primary care for which medical reversals have occurred.

Methods: We recently identified almost 400 medical practices that were used in clinical care before they were tested in well-done randomized controlled trials and subsequently were found to be ineffective or harmful.

Results: We review several of these practices commonly used in family medicine, which include arthroscopy for osteoarthritis of the knee, opioids for common causes of pain, and aspirin and continuous positive airway pressure for the prevention of cardiovascular disease.

Conclusions: Although these practices were implemented because of sound biologic plausibility or encouraging observational data, well done randomized controlled trials have failed to show evidence of effectiveness. These examples raise caution in introducing new clinical interventions into widespread clinical practice without sufficient high-quality evidence demonstrating efficacy.

© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Primary care physicians treat a wide variety of conditions that require a broad knowledge base in the face of ever-evolving literature. Truisms that were taught in medical school and residency, or that are promulgated to the public, may not stand up to further research, and in fact, be reversed because of evidence from high-quality studies. Situations where medical practices are implemented and then are later found to be either ineffective or harmful (when compared against prior or lesser standards) through properly conducted randomized controlled trials (RCTs) are referred to as medical reversals.1,2 Recent work has identified almost 400 of these medical practices in a variety of medical disciplines and conditions.3 These practices were identified by reviewing RCTs in 3 high-impact medical journals (published 2003–2017), and represented almost all medical disciplines. Of 396 medical reversals identified in the original research, this article provides a focused summary of reversals of interest to primary care clinicians specifically, given the frequency of the conditions and persistent widespread use of the interventions. Here, we focus on 3 common clinical situations encountered in primary care for which medical reversals have occurred.4 We have chosen to highlight these specific practices because of their relevance to primary care, the frequency of the conditions, the historical belief in the benefit of these interventions, and identified reversals that call into question the routine use of these medical practices.

Knee Pain

Millions of people in the United States have symptomatic knee osteoarthritis, affecting 10% to 13% of adults aged 60 years and older.5 Guidelines strongly support participation in self-management programs, physical activity, strength training, and other low-impact exercises for those with symptomatic knee osteoarthritis.6 However, despite inconsistent recommendations for more invasive treatments, hundreds of thousands in the United States are treated with corticosteroid injections and surgery.7,8 Although these practices are common, randomized trials have failed to produce evidence for their effectiveness.
For example, because corticosteroids have an anti-inflammatory effect and because osteoarthritis is an inflammatory condition, intra-articular corticosteroids have been used for several decades, and as many as 95% of rheumatologists use them for osteoarthritis; however, in a randomized trial of patients with symptomatic knee osteoarthritis, in which 140 patients were treated with an injection of either triamcinolone or saline every 12 weeks for 2 years, there were no differences in pain (difference = –0.6 on a scale of 0–20; 95% CI, –1.6 to 0.3) between patients treated with triamcinolone or saline. Further, patients assigned to the triamcinolone treatment had a greater loss in cartilage thickness.

Many cases of osteoarthritis involve meniscal tears that are often treated with surgery to repair or remove the loose areas of degenerative cartilage, reduce swelling and pain, and preserve the knee from further damage. More than 365,000 people were treated with knee arthroscopy in 2006 for a tear of the meniscus, an increase of about 25% from 10 years prior, making it among the most commonly performed orthopedic surgeries. Because it is unknown whether pain and other symptoms in patients with osteoarthritis come from meniscal tears, osteoarthritis, or both, there is question as to the effectiveness of knee arthroscopy in patients with osteoarthritis.

In 1 trial, patients with symptomatic and image-detected osteoarthritis and a meniscal tear (N = 351) were assigned to either surgery and postoperative physical therapy or a standardized physical therapy regimen. After 6 months, there were no differences in physical function scores between the 2 groups (mean difference = 2.4 points on a 100-point scale; 95% CI, –1.8 to 6.5). Although there were a notable number of patients in the physical therapy only arm who also received surgery (30%), these results suggest that routine knee arthroscopy in all patients with osteoarthritis and meniscal tear is unwarranted.

Another trial has similarly cast doubt on the utility of meniscus surgery, even in the absence of arthritis. In this trial, 146 symptomatic patients with a meniscal tear but no evidence of osteoarthritis were assigned to either arthroscopic partial meniscectomy or sham surgery. After 12 months of follow-up, there was no difference in physical functioning scores between the 2 groups (difference = –2.5 points on a 100-point scale; 95% CI, –9.2 to 4.1). These studies collectively show that degenerative conditions of the knee do not benefit from routine invasive treatments such as corticosteroid injections and surgery. These patients are likely better off with a less-is-more approach of low-impact physical activity and strength training exercises.

Opioids for Pain

Pain is a common reason people visit the emergency department and patients are often prescribed an opioid medication to treat the pain. Recent news has brought attention to the origins of the current opioid epidemic. The deception and downplaying of the addictiveness of these drugs is certainly a cause for concern, but recent studies have provided evidence that opioids are no more effective in treating common conditions in the emergency setting than other less-addictive treatments. Back and neck pain are among the top reasons people are prescribed opioids, and yet the superiority of opioids in treating these conditions over other common pain analgesics has not been established.

One trial randomized 323 patients in the emergency department with nontraumatic lower back pain to naproxen plus either oxycodone/acetaminophen, cyclobenzaprine, or placebo. There were no differences in Roland-Morris Disability Questionnaire among the 3 treatment regimens (placebo = 8.9; 95% CI, 7.3–10.5; cyclobenzaprine = 8.2; 95% CI, 6.2–9.4; and oxycodone/acetaminophen = 7.8; 95% CI, 6.6–9.8).

Another trial randomized 416 patients who presented in the emergency department with acute extremity pain to aspirin plus 1 of 3 opioid treatments (5 mg oxycodone, 5 mg ibuprofen, or 30 mg codeine) or one nonopioid treatment (400 mg ibuprofen). All groups had favorable changes in pain 2 hours after receiving treatment, but changes in pain intensity were no different between the aspirin plus ibuprofen group and any of the aspirin plus opioid groups (largest difference in pain was 0.8 on an 11-point scale; 95% CI, –0.2 to 1.7).

RCTs of in patients with chronic pain in the primary care setting have also failed to provide evidence of effectiveness. Patients (N = 240) in the Strategies for Prescribing Analgesics Comparative Effectiveness RCT who had chronic pain from back pain or hip or knee osteoarthritis and who were not responding to traditional analgesic use were assigned to either an opioid therapy or a nonopioid therapy. After 12 months, there were no differences in pain-related function between the groups (difference = 0.1 on a scale of 0–10; 95% CI, –0.5 to 0.7), and pain intensity was better in the nonopioid group (difference = 0.5 on a scale of 0–10; 95% CI, 0.0–1.0).

The results from these trials show that, regardless of the potential addictiveness of these drugs, opioids are no better at controlling pain for common acute painful conditions than other nonopioid analgesics, and yet this practice became widely used before solid evidence of their effectiveness was established.

Cardiovascular Disease Prevention

Aspirin

Whether or not to take aspirin for the prevention of cardiovascular disease has been a heavily discussed topic. The US Preventive Services Task Force currently recommends aspirin for the prevention of cardiovascular disease in patients aged 50 to 59 years who are at an elevated risk of cardiovascular disease. Other professional groups, including the American Heart Association and American Diabetes Association have made similar recommendations. Perhaps because of extrapolation of these guidelines to other populations, many people have taken aspirin to prevent cardiovascular disease, even those who are average- or low-risk of cardiovascular disease.

However, in the Japanese Primary Prevention Project, 14,464 patients aged 60 to 85 years with a history of hypertension, dyslipidemia, or diabetes were randomly assigned to either aspirin (100 mg/d) or no aspirin, in addition to any ongoing medications. There were no differences in the composite outcome (death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction) between those assigned to the aspirin group and those assigned to the no aspirin group (2.77% vs 2.96%; P = .54) over 6 years.

Even in patients with other risk factors, aspirin for the prevention of cardiovascular disease does not seem to be effective. In a randomized trial of 2,539 patients with type 2 diabetes and no history of cardiovascular disease, patients were assigned to either 81 to 100 mg aspirin once daily or no regular use of aspirin. After an average of 4.4 years follow-up, there was no difference in the rates of atherosclerotic events between the groups (hazard ratio = 0.80; 95% CI, 0.58–1.10).

These results were just the beginning of studies showing a lack of benefit for the preventive nature of aspirin. The Aspirin to Reduce Risk of Initial Vascular Events study was an international RCT looking at the effects of aspirin in 12,546 patients with average cardiovascular risk and without diabetes. Patients who received 100 mg aspirin daily did not have lower rates of the composite outcome (ie, cardiovascular death, myocardial infarction, unsta-
ble angina, stroke, or transient ischemic attack [HR = 0.96; 95% CI, 0.81–1.13]) after 5 years.

These results confirm that aspirin provides no benefit to patients who are at low or average risk of cardiovascular disease, and even suggests that aspirin does not benefit all patients who are at higher risk. Again, this practice has been regularly used despite of a lack of data to support its use in patients with average to low-risk likely because of overgeneralizing results of other studies in high-risk populations.

**Obstructive sleep apnea and cardiovascular disease**

Observational studies have shown an association between obstructive sleep apnea (OSA) and more cardiovascular events. This association is not necessarily direct, as individuals with OSA also often have other risk factors for cardiovascular disease, such as obesity and hypertension. Continuous positive airway pressure (CPAP) has been recommended for patients with moderate to severe sleep apnea because it was observed that OSA was associated with poor markers of cardiovascular disease (increased sympathetic activity and inflammatory mediators and decreased endothelial function), but some recommend CPAP treatment for individuals with less-serious OSA and cardiovascular risk factors.

In the Sleep Apnea Cardiovascular Endpoints RCT, the effectiveness of CPAP was evaluated in patients with OSA and either coronary artery disease or cerebrovascular disease and no severe daytime sleepiness. Patients (N = 2717) were assigned to either CPAP plus usual care or usual care only. After 3.7 years of follow-up, patients assigned to the CPAP group had fewer apnea or hypopnea events per hour but did not have improvements in the primary event (ie, death from cardiovascular causes; myocardial infarction; stroke; or hospitalization for unstable angina, heart failure, or transient ischemic attack [17.0% participants vs 15.6%; P = 0.34]). In another RCT of normotensive patients with OSA and no daytime sleepiness, 725 patients were randomized to either CPAP treatment or no CPAP treatment. After a median of 4 years of follow-up, there were no differences in the incidence density rate between those assigned to CPAP and those assigned to no CPAP (9.20 vs 11.20 per 100 person-years; P = 0.20).

In this case, it appears that biologic plausibility may have spurred individuals to initially adopt this practice. Despite OSA being associated with cardiovascular disease, evidence to date has not supported that treatment of OSA with CPAP yields any improvement in cardiovascular outcomes.

**Conclusions**

We identified several common primary care conditions in which new, higher-quality evidence has reversed the prior understanding of effective treatments. In many situations, these interventions were adopted based on limited, lower-quality evidence, biologic plausibility, and expert opinion. These treatments have become widespread in clinical practice despite the lack of high-quality supporting evidence. Even with RCTs demonstrating the inefficacy of some of these therapies, reversing these ineffective and/or harmful practices is still a major effort. These examples raise caution in introducing new clinical interventions into widespread clinical practice without sufficient high-quality evidence, as well as remind us of the continual need to appraise the evidence, even for time-honored clinical interventions.

**Acknowledgments**

Dr Prasad reports receiving royalties from his book *Ending Medical Reversal*; is funded by the Laura and John Arnold Foundation; has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, and professional societies, and is a writer for Medscape. Dr Livingston reports serving as a consultant to Oregon’s Health Evidence Review Commission, serving as a consultant and co-investigator on 2 research studies evaluating a statewide back pain policy, and previously served as a consultant to the American College of Preventive Medicine.

**Author contributions**

AH, CL, and VP selected and reviewed medical reversals to be included in this article; AH wrote the first draft and CL and VP reviewed and edited drafts.

**Conflicts of Interests**

Dr Prasad is host of Plenary Session podcast, which has Patreon backers. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

**References**

1. Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an analysis of 144 contradicted medical practices. Mayo Clinic Proceedings. Elsevier; 2013:88:790–798.
2. Prasad V, Gall V, Cifu A. The frequency of medical reversal. Arch Intern Med. 2011;171:1675–1678.
3. Herrera-Perez D, Haslam A, Crain T, et al. Meta-Research: A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. eLife. 2019;8:e45183.
4. Finley CR, Chan DS, Garrison S, et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64:832–840.
5. Zhang Y, Jordan J. Epidemiology of obstructive sleep apnea. Clin Geriatr Med. 2010;26:355–369.
6. Hauk LJ. Treatment of knee osteoarthritis: a clinical practice guideline from the AAOS. Am Fam Physician. 2014;90:918.
7. Kim S, Bosque J, Meehan JP, et al. A matter of increased sleep apnea screening in patients with osteoarthritis. The New England journal of medicine. 2019;380:1967–1973.
8. Prasad V, Finley E, Pandit SJ. Treatment of knee osteoarthritis. Am Fam Physician. 2011;83.
9. Uthman I, Raynauld J, Harauzi B. Intra-articular therapy in osteoarthritis. Postgrad Med J. 2003;79:449–453.
10. McClendon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular trimethadione vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017;318:1967–1973.
11. Sihvonen R, Pauola M, Malmivaara A, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. New Engl J Med. 2013;369:2515–2524.
12. Fletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299:70–78.
13. Sivastava AB, Gold MS. Beyond supply: how we must tackle the opioid epidemic. Mayo Clinic Proceedings Elsevier; 2018:269–272.
14. Yang BK, Stort CL, Teiskoff AM, Soha M, Idzik SK, McKimmion M. National opioid prescribing trends in emergency departments by provider type: 2005–2015. Am J Emerg Med. 2019;37(8):1439–1445.
15. Friedman BW, Dym AA, Davitt M, et al. Naproxen with cyclobenzaprine, oxycodone/acetaminophen, or placebo for treating acute low back pain: a randomised clinical trial. JAMA. 2015;314:1572–1580.
16. Chang AK, Bijur PE, Essex D, Barnaby BP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremism pain in the emergency department: a randomized clinical trial. JAMA. 2017;318:1661–1667.
17. Krebs EE, Gravelly A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319:872–882.
18. Bimbos-Domingo KParX, Aspin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836–845.
19. Pignone M, Alberts M, Coyle J, et al. American Diabetes Association American Heart Association American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American
Heart Association, and an expert consensus document of the American College of Cardiology Foundation. 2010;33:1395–1402.

23. Kaplan K. Too many people take aspirin to prevent heart attacks, stroke, study says. Los Angeles Times; 2015.

24. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510–2520.

25. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–2141.

26. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–1046.

27. Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clinic Proceedings Elsevier; 2004:1036–1046.

28. Center for Medicare & Medicaid Services. Decision memo for continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA)(CAG-00093 N) 2001.

29. McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. New Engl J Med. 2016;375:919–931.

30. Barbe F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA. 2012;307:2161–2168.